Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

NCT03578029 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Business Decision

Conditions

Junctional Epidermolysis Bullosa
Dystrophic Epidermolysis Bullosa

Interventions

DRUG: RGN-137
DRUG: Placebo

Sponsor

Lenus Therapeutics, LLC